Frontiers in Immunology (Jan 2023)
CK2β-regulated signaling controls B cell differentiation and function
- Laura Quotti Tubi,
- Laura Quotti Tubi,
- Elisa Mandato,
- Elisa Mandato,
- Elisa Mandato,
- Sara Canovas Nunes,
- Sara Canovas Nunes,
- Sara Canovas Nunes,
- Arash Arjomand,
- Arash Arjomand,
- Fortunato Zaffino,
- Fortunato Zaffino,
- Sabrina Manni,
- Sabrina Manni,
- Alessandro Casellato,
- Alessandro Casellato,
- Paolo Macaccaro,
- Paolo Macaccaro,
- Nicola Vitulo,
- Sara Zumerle,
- Odile Filhol,
- Brigitte Boldyreff,
- Christian W. Siebel,
- Antonella Viola,
- Giorgio Valle,
- Federica Mainoldi,
- Stefano Casola,
- Valeria Cancila,
- Alessandro Gulino,
- Claudio Tripodo,
- Claudio Tripodo,
- Marco Pizzi,
- Angelo Paolo Dei Tos,
- Livio Trentin,
- Livio Trentin,
- Gianpietro Semenzato,
- Gianpietro Semenzato,
- Francesco Piazza,
- Francesco Piazza
Affiliations
- Laura Quotti Tubi
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Laura Quotti Tubi
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- Elisa Mandato
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Elisa Mandato
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- Elisa Mandato
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
- Sara Canovas Nunes
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Sara Canovas Nunes
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- Sara Canovas Nunes
- Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States
- Arash Arjomand
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Arash Arjomand
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- Fortunato Zaffino
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Fortunato Zaffino
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- Sabrina Manni
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Sabrina Manni
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- Alessandro Casellato
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Alessandro Casellato
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- Paolo Macaccaro
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Paolo Macaccaro
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- Nicola Vitulo
- Department of Biology, Interdepartmental Research Center for Biotechnologies (CRIBI) Biotechnology Center, University of Padova, Padova, Italy
- Sara Zumerle
- Department of Biomedical Sciences, University of Padova, Padova, Italy
- Odile Filhol
- Institut National de la Santé Et de la Recherche Médicale (INSERM) U1036, Institute de Recherches en Technologies et Sciences pour le Vivant/Biologie du Cancer et de l’Infection, Grenoble, France
- Brigitte Boldyreff
- Kinase Detect ApS, Krusaa, Denmark
- Christian W. Siebel
- Department of Discovery Oncology, Genentech, Inc., South San Francisco, CA, United States
- Antonella Viola
- Department of Biomedical Sciences, University of Padova, Padova, Italy
- Giorgio Valle
- Department of Biology, Interdepartmental Research Center for Biotechnologies (CRIBI) Biotechnology Center, University of Padova, Padova, Italy
- Federica Mainoldi
- 0IFOM-ETS-The AIRC Institute of Molecular Oncology, Milan, Italy
- Stefano Casola
- 0IFOM-ETS-The AIRC Institute of Molecular Oncology, Milan, Italy
- Valeria Cancila
- 1Tumor Immunology Unit, University of Palermo, Palermo, Italy
- Alessandro Gulino
- 1Tumor Immunology Unit, University of Palermo, Palermo, Italy
- Claudio Tripodo
- 0IFOM-ETS-The AIRC Institute of Molecular Oncology, Milan, Italy
- Claudio Tripodo
- 1Tumor Immunology Unit, University of Palermo, Palermo, Italy
- Marco Pizzi
- 2Department of Medicine, Cytopathology and Surgical Pathology Unit, University of Padova, Padova, Italy
- Angelo Paolo Dei Tos
- 2Department of Medicine, Cytopathology and Surgical Pathology Unit, University of Padova, Padova, Italy
- Livio Trentin
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Livio Trentin
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- Gianpietro Semenzato
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Gianpietro Semenzato
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- Francesco Piazza
- Department of Medicine, Division of Hematology, University of Padova, Padova, Italy
- Francesco Piazza
- Unit of Normal and Malignant Hematopoiesis, Laboratory of Myeloma and Lymphoma Pathobiology, Veneto of Molecular Medicine (VIMM), Padova, Italy
- DOI
- https://doi.org/10.3389/fimmu.2022.959138
- Journal volume & issue
-
Vol. 13
Abstract
Serine-Threonine kinase CK2 supports malignant B-lymphocyte growth but its role in B-cell development and activation is largely unknown. Here, we describe the first B-cell specific knockout (KO) mouse model of the β regulatory subunit of CK2. CK2βKO mice present an increase in marginal zone (MZ) and a reduction in follicular B cells, suggesting a role for CK2 in the regulation of the B cell receptor (BCR) and NOTCH2 signaling pathways. Biochemical analyses demonstrate an increased activation of the NOTCH2 pathway in CK2βKO animals, which sustains MZ B-cell development. Transcriptomic analyses indicate alterations in biological processes involved in immune response and B-cell activation. Upon sheep red blood cells (SRBC) immunization CK2βKO mice exhibit enlarged germinal centers (GCs) but display a limited capacity to generate class-switched GC B cells and immunoglobulins. In vitro assays highlight that B cells lacking CK2β have an impaired signaling downstream of BCR, Toll-like receptor, CD40, and IL-4R all crucial for B-cell activation and antigen presenting efficiency. Somatic hypermutations analysis upon 4-Hydroxy-3-nitrophenylacetyl hapten conjugated to Chicken Gamma Globulin (NP-CGG) evidences a reduced NP-specific W33L mutation frequency in CK2βKO mice suggesting the importance of the β subunit in sustaining antibody affinity maturation. Lastly, since diffuse large B cell lymphoma (DLBCL) cells derive from GC or post-GC B cells and rely on CK2 for their survival, we sought to investigate the consequences of CK2 inhibition on B cell signaling in DLBCL cells. In line with the observations in our murine model, CK2 inactivation leads to signaling defects in pathways that are essential for malignant B-lymphocyte activation.
Keywords
- B lymphocyte
- B cell development
- protein kinase CK2
- marginal zone
- germinal center
- Diffuse large B cell lymphoma